JP2001231497A - Functional food - Google Patents

Functional food

Info

Publication number
JP2001231497A
JP2001231497A JP2000044242A JP2000044242A JP2001231497A JP 2001231497 A JP2001231497 A JP 2001231497A JP 2000044242 A JP2000044242 A JP 2000044242A JP 2000044242 A JP2000044242 A JP 2000044242A JP 2001231497 A JP2001231497 A JP 2001231497A
Authority
JP
Japan
Prior art keywords
functional food
trout
salmon
sap
chondroitin sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000044242A
Other languages
Japanese (ja)
Other versions
JP4034024B2 (en
Inventor
Akinori Suginaka
昭典 杉中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RINOKIA KK
Original Assignee
RINOKIA KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RINOKIA KK filed Critical RINOKIA KK
Priority to JP2000044242A priority Critical patent/JP4034024B2/en
Publication of JP2001231497A publication Critical patent/JP2001231497A/en
Application granted granted Critical
Publication of JP4034024B2 publication Critical patent/JP4034024B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

PROBLEM TO BE SOLVED: To enable a functional food for promoting the diuretic while simultaneously cleaning the blood without excessively restricting the diet to be safely and inexpensively supplied in large amount. SOLUTION: This functional food contains chondroitin sulfuric acid derived from the nasal cartilage of a salmon or a trout, and sap of a tree belonging to the genus Butula of Betulaceae. In one case, the functional food is a soft jerry shape consisting essentially of the chondroitin sulfuric acid, and in the other case, the functional food is a liquid drink consisting essentially of the sap of the tree belonging to the genus Butula of Betulaceae. The chondroitin sulfuric acid is preferably obtained by pulverizing the nasal cartilage of the salmon or the trout, removing the fat from the pulverized product, decomposing the resultant product by using an alkali, subjecting the decomposed product to oxygen treatment, and purifying and extraction-treating the oxygen treated material, and the pulverizing of the nasal cartilage of the salmon or the trout is preferably carried out under a low temperature condition of -30 to -60 deg.C.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【産業上の利用分野】本発明はコンドロイチン硫酸を含
む機能性食品に係り、とくに肥満、関節痛、通風を軽減
するための機能性食品を大量・安全に製造する技術に関
する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a functional food containing chondroitin sulfate, and more particularly to a technique for mass-producing and safely producing a functional food for reducing obesity, joint pain and ventilation.

【0002】[0002]

【従来の技術】健康に良好な結果をもたらすいわゆる機
能性食品は、日常の生活習慣の中で容易に摂取が可能で
あり、医薬品のように処方が限定されないことから、健
康に注意を払う者は継続的にある種の成分を食事の一環
として摂取する。
2. Description of the Related Art A so-called functional food which gives good results to health can be easily taken in daily life habits and its prescription is not limited as in pharmaceuticals. Consumes certain ingredients continuously as part of a diet.

【0003】近時知られるようになった健康食品として
は、ビタミン補給のもの、骨を強化するものなどがあ
る。本発明に係る食品は、主として肥満・関節痛・通風
を軽減するものである。肥満にしろ関節痛にしろ、その
原因は雑多であると考えられ、当該食品を摂取すれば健
康上の問題が直ちに解決するわけではない。しかし、肥
満、関節痛、痛風などの症状にはある種の共通した傾向
ないし相関がみられる。肥満は食べ過ぎが最も基本的な
原因である。それ自体としては病気とも呼べないが、肥
満に伴う関節痛ないし痛風に到る経緯は、医学上も健康
を害している状態といえ、尿酸過多等の食物原因および
体内機能の低下が関係するといわれる。
[0003] Health foods that have recently become known include those supplemented with vitamins and those that strengthen bones. The food according to the present invention mainly reduces obesity, joint pain and ventilation. The cause, whether obese or joint pain, is thought to be heterogeneous and ingesting the food does not immediately resolve health problems. However, symptoms such as obesity, joint pain and gout have certain common trends or correlations. Obesity is the most basic cause of overeating. Although it can not be called a disease in itself, the history of arthralgia or gout associated with obesity can be said to be medically harmful to health, and it is related to food causes such as excessive uric acid and decreased body function. Will be

【0004】この点に関しては、例えば特開平7−25
5416号公報記載の発明が知られている。これは、フ
カヒレ等から収得できるコンドロイチン硫酸(ムコ多
糖)を主成分として含むもので、コンドロイチン硫酸に
セレニウム等の必須微量ミネラルを添加した機能性食品
である。この発明においてはコンドロイチン硫酸が古く
から老化防止、滋養強壮に効果的であることが指摘され
ており、セレニウムに関しては体内でのグルタチオンペ
ルオキシターゼの構成成分となり、過酸化脂質に起因す
る連鎖反応的な組織の酸化を防止できるとした上で、老
化防止、特に精力減退を防止する上で効果的であるとす
る。
Regarding this point, for example, Japanese Patent Application Laid-Open No. 7-25 / 1995
The invention described in Japanese Patent No. 5416 is known. This is a functional food containing, as a main component, chondroitin sulfate (mucopolysaccharide) obtainable from shark fin or the like, and is a chondroitin sulfate to which essential trace minerals such as selenium are added. In the present invention, it has been pointed out that chondroitin sulfate is effective in preventing aging and nourishing tongue for a long time.For selenium, it becomes a component of glutathione peroxidase in the body, and a chain-reactive tissue caused by lipid peroxide. It is said that it is effective in preventing aging and, in particular, in preventing dysfunction.

【0005】また特開平7−308169号公報記載の
発明は、獣骨骨髄から得られるマローエキス、とくにコ
ンドロイチン硫酸に代表されるムコ多糖が多様な成分を
生理活性機能を呈することを指摘した上で、これをリュ
ーマチ効果に優れた成分であるとする。
The invention described in Japanese Patent Application Laid-Open No. 7-308169 has pointed out that a malo extract obtained from animal bone marrow, in particular, a mucopolysaccharide typified by chondroitin sulfate exhibits various components with a physiologically active function. This is considered to be a component excellent in rheumatic effect.

【0006】一方、シラカンバ(ベルコウサカンバ等の
他のカバノキ科樹木を含む;以下同じ)に関しては、そ
のオガクズを培地にしたカバノアタケ菌糸体から有効エ
キスを抽出することにより薬品または食品に応用する技
術が提案されている(特開平10−323168号)。
この提案では、カバノアタケの抽出エキスから抗ガン成
分を抽出できる旨が指摘されている。
[0006] On the other hand, for birch (including other birch trees such as birch birch; the same applies hereinafter), a technique of applying an effective extract from a mycelium of a birch on a sawdust as a medium to apply it to a drug or a food. Has been proposed (JP-A-10-323168).
In this proposal, it is pointed out that an anticancer component can be extracted from an extract of birch.

【0007】[0007]

【発明が解決しようとする課題】コンドロイチン硫酸
が、リューマチ等、人体の関節部位に作用して良好な結
果を得ることは前記特開平7−255416号公報の指
摘の通りであり、古くから中国の食医学に関する文献に
も記載され周知である。
The fact that chondroitin sulfate acts on the joints of the human body such as rheumatism and obtains good results is as pointed out in the above-mentioned Japanese Patent Application Laid-Open No. Hei 7-255416. It is well known and described in the literature on food medicine.

【0008】ところで、コンドロイチン硫酸に関する問
題は、フカヒレや牛骨骨髄を主原料とするために製造コ
ストが著しく高くなる点にある。古くから知られている
コンドロイチン硫酸の取得は、主としてフカヒレ由来
(鮫由来)であり、現時点でいえば1kgの販売取引価
格は平均15〜16万円になる。
[0008] A problem with chondroitin sulfate is that the production cost is significantly increased because shark fin or bovine bone marrow is used as a main raw material. Acquisition of chondroitin sulfate, which has been known for a long time, is mainly derived from shark fins (sharks). At present, the selling transaction price of 1 kg is 150,000 to 160,000 yen on average.

【0009】関節疾患に有効とされるコンドロイチン硫
酸の一日の摂取量は、平均1gとされる。従ってフカヒ
レ由来のコンドロイチン硫酸を使用する場合は、少なく
とも原価で150〜160円以上のコストを消費者が負
担する必要がある。これに他の成分を添加すると製造コ
ストの実費だけでも200円を超え、輸送コストや販売
コストを勘案すると一日の最低摂取量を確保するだけで
相当額の負担を強いられる。結果として、日常的継続的
な摂取は難しい状況にある。
[0009] The daily intake of chondroitin sulfate, which is effective for joint diseases, is 1 g on average. Therefore, when using chondroitin sulfate derived from shark fin, the consumer must bear at least a cost of 150 to 160 yen or more. If other components are added to this, the actual production cost alone will exceed 200 yen, and in consideration of transportation costs and sales costs, securing a minimum daily intake will impose a considerable burden. As a result, daily continuous intake is difficult.

【0010】牛骨骨髄由来のコンドロイチン硫酸は、骨
髄の原価はフカヒレに較べると格段に安い。しかしなが
ら、原材料の重量に比して収量が少なく、また狂牛病の
ような感染症の虞れがあり、安全性の点で不安が残る。
[0010] Chondroitin sulfate derived from bovine bone marrow has a much lower bone marrow cost than shark fins. However, the yield is small compared to the weight of the raw materials, and there is a risk of infectious diseases such as mad cow disease, which leaves concerns about safety.

【0011】一方、多くの場合、関節疾患は肥満してい
る者に多くみられ、軽度の関節痛からリューマチや痛風
という経緯を辿る。これらの因果関係は、肥満に起因す
る心肺機能の低下ないし血中糖分、尿の酸性度などが指
摘される。必要な処置としては、第一に過度の肥満の防
止、血中酸度(糖分)の浄化と軽減である。
[0011] On the other hand, in many cases, joint diseases are often observed in obese persons, and follow a history from mild joint pain to rheumatism or gout. These causal relationships are pointed out by a decrease in cardiopulmonary function due to obesity, blood sugar, urine acidity, and the like. The necessary treatment is, first of all, prevention of excessive obesity and purification and reduction of blood acidity (sugar content).

【0012】これは最も簡単には食餌制限と利尿の促進
によって達成できる。しかし肥満は病害ではないと考え
られることから初期段階における食餌制限は難しいし、
また利尿促進といっても、単なる水分補給では血液の浄
化や肥満防止はできない。そこで、極端な食餌制限を強
制することなく、また利尿作用を高めるために水分とは
別に血中の酸や糖を分解して速やかに体外に排出する機
能成分の摂取が望まれる。
This can be achieved most simply by restricting food and promoting diuresis. However, obesity is not considered a disease, so it is difficult to restrict food in the early stages.
Even though diuresis is promoted, mere hydration cannot purify blood or prevent obesity. Therefore, in order to enhance the diuretic effect without forcing an extreme dietary restriction, it is desired to ingest a functional component which degrades acids and sugars in the blood and rapidly excretes outside the body in addition to water.

【0013】本発明の目的は、過度の食餌制限をするこ
となく、同時に血液を浄化しつつ利尿を促進する機能性
食品を、可能な限り大量、安全、安価に製品供給可能と
することにある。
An object of the present invention is to provide a functional food that promotes diuresis while purifying blood without excessively restricting the diet at the same time as much as possible, safely and inexpensively. .

【0014】[0014]

【課題を解決するための手段】前記目的を達成するため
本発明に係る機能性食品は、鮭または鱒の鼻軟骨由来の
コンドロイチン硫酸と、カバノキ科カバノキ属樹木の樹
液とを含む。
Means for Solving the Problems To achieve the above object, a functional food according to the present invention comprises chondroitin sulfate derived from nasal cartilage of salmon or trout and sap of a birch tree of the birch family.

【0015】この機能性食品はコンドロイチン硫酸を主
成分とする軟質ゼリー状とする場合があり、カバノキ科
カバノキ属樹木の樹液を主成分とする液状飲料とする場
合がある。
The functional food may be in the form of a soft jelly containing chondroitin sulfate as a main component, and may be a liquid beverage mainly containing sap of a birch tree of the birch family.

【0016】コンドロイチン硫酸は、鮭または鱒の鼻軟
骨を粉砕して脱脂しアルカリを用いて分解させた後、酵
素処理を施して精製抽出することが望ましく、鮭または
鱒の鼻軟骨の粉砕は、マイナス30〜60℃の低温条件
下で行うことが望ましい。
[0016] Chondroitin sulfate is desirably crushed by crushing salmon or trout nasal cartilage, defatting it with an alkali, and then subjecting it to enzymatic treatment for purification and extraction. It is desirable to carry out under a low temperature condition of minus 30-60 ° C.

【0017】[0017]

【作用】本発明に係る機能性食品は、鮭または鱒の鼻軟
骨由来のコンドロイチン硫酸と、カバノキ科カバノキ属
樹木の樹液とを含む。鮭または鱒の鼻軟骨由来のコンド
ロイチン硫酸を原料とするのは、フカヒレ由来のコンド
ロイチン硫酸と比較して、最終的に得られる機能成分が
略同一であり、大量取得が可能であって価格が圧倒的に
低減するからである。また牛骨骨髄由来のコンドロイチ
ン硫酸に較べ、感染症などの安全面での危険がなく、し
かも同一コストで大量収得が可能である。
The functional food according to the present invention contains chondroitin sulfate derived from nasal cartilage of salmon or trout, and sap of a birch tree of the birch family. Chondroitin sulfate derived from nasal cartilage of salmon or trout is used as a raw material, as compared to shark fin-derived chondroitin sulfate, the functional components finally obtained are almost the same, large quantities can be obtained, and the price is overwhelming This is because it is reduced in total. Compared to chondroitin sulfate derived from bovine bone marrow, there is no danger in terms of safety such as infectious diseases, and a large amount can be obtained at the same cost.

【0018】一方、カバノキ科カバノキ属樹木の樹液を
用いるのは、利尿作用を促進し体内血液の浄化を図るた
めである。またカバノキ科カバノキ属樹木の樹液(例え
ばシラカバ樹液)を用いることにより、特有の芳香に起
因する精神鎮静作用など日常的に摂取する食品としての
機能性を高めることが出来る。シラカバ樹液は、北海道
や北方圏諸外国から比較的安価に入手できる。
On the other hand, the reason for using the sap of the birch tree of the birch family is to promote the diuretic effect and purify the blood in the body. In addition, by using a sap of a birch tree of the birch family (for example, birch sap), it is possible to enhance the functionality as a food to be taken on a daily basis, such as a tranquilizing effect caused by a unique aroma. Birch sap can be obtained relatively cheaply from Hokkaido and other countries in the northern region.

【0019】コンドロイチン硫酸を主成分とする場合
(配合比を多くする場合)は、水分添加によりゼリー状
食品となり、カバノキ科カバノキ属樹木の樹液を主成分
とする場合(配合比を多くする場合)は、液状の飲料食
品(ドリンク剤)となる。
When chondroitin sulfate is the main component (when the mixing ratio is increased), it becomes a jelly-like food by adding water, and when the sap of the birch tree of the birch family is used as the main component (when the mixing ratio is increased). Is a liquid beverage (drink).

【0020】コンドロイチン硫酸は、腸管におけるグル
コース吸収を遅らせ血糖値の急激な上昇を抑える。肥満
の原因は、腸管から吸収されたグルコースによって血糖
値(グルコース濃度)が上昇し、これを抑えるために膵
臓からインシュリンが分泌され、グルコースが脂肪細胞
に取り込まれて脂肪の合成と貯蔵に利用される結果と考
えられる。従って、腸管におけるグルコースの吸収が遅
れた場合はインシュリン分泌による脂肪細胞へのグルコ
ースの貯留という現象は阻却され、同一の食事内容でも
結果的に肥満しにくい効果を得る。
Chondroitin sulfate delays glucose absorption in the intestinal tract and suppresses a sharp rise in blood sugar level. The cause of obesity is that glucose absorbed from the intestinal tract increases blood glucose (glucose concentration), and insulin is secreted from the pancreas to suppress this, and glucose is taken up by fat cells and used for fat synthesis and storage. It is considered to be the result. Therefore, when the absorption of glucose in the intestinal tract is delayed, the phenomenon that glucose is stored in fat cells due to insulin secretion is prevented, and as a result, obesity is less likely to occur even with the same dietary content.

【0021】コンドロイチン硫酸の取得は、鮭または鱒
の鼻軟骨を粉砕して脱脂し、アルカリを用いて分解させ
た後、酵素処理を施して精製抽出することが望ましい。
粉砕した後に取得処理を行うのは、脱脂を効率的にする
ためである。原材料重量に対する収量%はフカヒレほど
に多くはないが、コスト的には格段に有利である。また
牛骨骨髄に較べると、原材料から得られる重量%に遜色
なく、破砕処理も容易であって、安全性やコストでは格
段に有利である。
In order to obtain chondroitin sulfate, it is desirable that the nasal cartilage of salmon or trout is crushed and defatted, decomposed with an alkali, and then subjected to enzymatic treatment for purification and extraction.
The reason why the acquisition process is performed after the pulverization is to make degreasing efficient. Although the yield percentage based on the weight of the raw material is not as large as that of shark fins, it is significantly advantageous in terms of cost. Also, compared to bovine bone marrow, the crushing process is easy as well as the weight percent obtained from the raw material, and the safety and cost are extremely advantageous.

【0022】鮭または鱒の鼻軟骨の粉砕を、マイナス3
0〜60℃の低温条件下で行うとするのは、破砕時の発
熱に起因するコンドロイチン硫酸の劣化損傷を防止し、
限られた原材料からより多くの良質なコンドロイチン硫
酸を得るためである。またマイナス30℃以下で粉砕す
ると、微粉砕が可能となり、粒度を揃えることも容易と
なる。
[0022] Grind the nose cartilage of salmon or trout by minus 3
Performing under a low temperature condition of 0 to 60 ° C. prevents deterioration of chondroitin sulfate caused by heat generation during crushing,
This is to obtain more high quality chondroitin sulfate from limited raw materials. In addition, when pulverization is performed at −30 ° C. or less, fine pulverization becomes possible, and it becomes easy to make the particle size uniform.

【0023】[0023]

【発明の実施の形態】鮭または鱒の鼻軟骨からコンドロ
イチン硫酸を抽出するには、次の製造ステップをとる。
DETAILED DESCRIPTION OF THE INVENTION The following manufacturing steps are used to extract chondroitin sulfate from salmon or trout nasal cartilage.

【0024】 原材料の取得 水産加工工場から排出される産業廃棄物としての鮭鱒頭
部を取得し、表皮、硬骨、肉粒などを除き、鼻軟骨のみ
を分離して−30℃以下、好ましくは−50℃の条件下
で鼻軟骨を粉砕し、主原料を得る。破砕機の回転数は原
料形状や全体重量に依存する。加工時の温度が低いほど
粒度を小さくできる。
Acquisition of Raw Materials A salmon trout head as industrial waste discharged from a fishery processing plant is obtained, and only nose cartilage is separated, except for epidermis, hard bone, meat grains, etc., at -30 ° C or lower, preferably The nasal cartilage is pulverized under the condition of −50 ° C. to obtain a main raw material. The number of revolutions of the crusher depends on the raw material shape and the overall weight. The lower the temperature during processing, the smaller the particle size.

【0025】 軟骨の脱脂 破砕した鼻軟骨の粉粒に十分な可食性の脱脂剤(例えば
アセトン)を加え、適当時間、例えば5〜15分の攪拌
を行う。アセトンの使用量は、主原料となる鼻軟骨粉粒
の等量倍以上、好ましくは1.5倍〜7倍を目安とす
る。等量でも脱脂は可能であるが処理時間が長くなるの
でコストを計算したうえで最適量を選択する。アセトン
の使用量を増やせば脱脂工程の処理は短縮できるがコス
トが嵩むため、通常は1.5〜3倍(重量比)のアセト
ンを用いる。
Defatting of Cartilage A sufficient edible defatting agent (for example, acetone) is added to the crushed nose cartilage powder, and the mixture is stirred for an appropriate time, for example, for 5 to 15 minutes. The amount of acetone used is approximately equal to or more than the equivalent of the nasal cartilage powder granules as the main raw material, preferably 1.5 to 7 times. Degreasing is possible even with the same amount, but the processing time becomes longer, so the cost is calculated and the optimum amount is selected. If the amount of acetone used is increased, the treatment in the degreasing step can be shortened, but the cost is increased. Therefore, usually 1.5 to 3 times (weight ratio) acetone is used.

【0026】脱脂処理は、好ましくは複数回おこなう。
上澄み液を捨て、新たな脱脂剤を補充して攪拌し、同一
処理を1〜2回くりかえす。そして最終的に沈殿を得て
乾燥させ、保存が必要な場合は低温、例えば−30℃程
度で保存する。
The degreasing treatment is preferably performed plural times.
Discard the supernatant, add new degreasing agent and stir, repeat the same process once or twice. Finally, a precipitate is obtained and dried, and if necessary, it is stored at a low temperature, for example, at about -30 ° C.

【0027】 アルカリ処理 脱脂済みの鼻軟骨粉粒を0.2M水酸化ナトリウムに溶
かし、適当時間の加温を行い、攪拌を加える。加温の温
度条件は30〜40℃、好ましくは37℃とする。処理
速度を高め、成分変化を抑えるためである。処理時間は
120〜180分の範囲である。この後、酢酸でpHを
7.0に中和する。
Alkaline Treatment The defatted nasal cartilage powder is dissolved in 0.2 M sodium hydroxide, heated for an appropriate time, and stirred. The temperature condition of the heating is 30 to 40 ° C, preferably 37 ° C. This is to increase the processing speed and suppress a change in components. Processing times range from 120 to 180 minutes. Thereafter, the pH is neutralized to 7.0 with acetic acid.

【0028】 プロナーゼ消化 0.2MTris-HCI緩衝液(pH7.8)を加え、酢酸カ
ルシウムを終濃度0.02Mになるよう加える。防腐の
ためメタノールを添加し、37℃の湯浴中において24
〜48時間加温する。この間は、必要に応じて攪拌を行
う。
Pronase digestion A 0.2 M Tris-HCI buffer (pH 7.8) is added, and calcium acetate is added to a final concentration of 0.02 M. Methanol was added for preservation, and in a hot water bath at 37 ° C, 24
Warm for ~ 48 hours. During this time, stirring is performed if necessary.

【0029】 エタノール沈殿 消化液を低温(例えば3〜5℃)で遠心分離し、上澄み
を濾過する。濾過液に5%相当の酢酸カルシウムを加
え、必要に応じて酢酸にてpH4.5に調整する。この
後、2倍量のエタノールを加えて24〜48時間放置す
る。
Ethanol precipitation The digest is centrifuged at low temperature (eg 3-5 ° C) and the supernatant is filtered. 5% calcium acetate is added to the filtrate, and the pH is adjusted to 4.5 with acetic acid as needed. Thereafter, double the amount of ethanol is added and the mixture is left for 24-48 hours.

【0030】 沈殿の洗浄と乾燥 エタノール液を低温(3〜5℃)で遠心分離し、沈殿を
回収する。ここに80%エタノールを加え、5〜12時
間ゆっくりと攪拌する。ここで再び遠心分離し、エタノ
ールを加えて洗浄する。エタノール濃度は初回よりも低
減してよい。洗浄の回数は2〜3回である。遠心分離に
より沈殿を回収し減圧法などの手段で乾燥する。
Washing and drying of the precipitate The ethanol solution is centrifuged at a low temperature (3 to 5 ° C.) to recover the precipitate. 80% ethanol is added thereto, and the mixture is slowly stirred for 5 to 12 hours. Here, it is centrifuged again, and washed by adding ethanol. The ethanol concentration may be reduced from the first time. The number of times of washing is 2-3 times. The precipitate is collected by centrifugation and dried by a method such as a reduced pressure method.

【0031】 精製 前処理として、DOWEX 50W×2陽イオン交換樹脂を、3N
HCL中で1〜2時間攪拌し、水洗後、2N HaOH中で1〜2
時間攪拌する。これを2〜3回繰り返し、水洗する。適
当カラム(例えば2.5×40cmカラム)の下に脱脂
綿を詰め、空気が入らないよう樹脂を詰める。
Purification As a pretreatment, DOWEX 50W × 2 cation exchange resin was mixed with 3N
Stir for 1-2 hours in HCL, wash with water, then 1-2 in 2N HaOH.
Stir for hours. This is repeated two to three times, and the product is washed with water. Under a suitable column (for example, a 2.5 × 40 cm column), a cotton wool is packed, and a resin is packed so that air does not enter.

【0032】次に、得られたムコ多糖(沈殿乾燥物)
を、ごく少量の脱イオン水に溶解しカラムに流して放置
する(30分程度)。カラムに樹脂体積の約4倍相当の
脱イオン水を流し、流出液をすぐに1N NaOHで中和す
る。
Next, the obtained mucopolysaccharide (dried precipitate)
Is dissolved in a very small amount of deionized water, allowed to flow through a column, and allowed to stand (about 30 minutes). The column is flushed with approximately 4 times the resin volume of deionized water and the effluent is immediately neutralized with 1N NaOH.

【0033】精製に際しては、中和液を脱イオン水中で
2〜3日透析する。これを濃縮し、フィルターを用いて
濾過してから乾燥させ(例えば冷凍乾燥)、鮭/鱒由来
のコンドロイチン硫酸を得る。
For purification, the neutralized solution is dialyzed in deionized water for 2-3 days. This is concentrated, filtered using a filter, and then dried (for example, freeze-dried) to obtain salmon / trout-derived chondroitin sulfate.

【0034】以上の操作により、脱脂済み鮭/鱒の鼻軟
骨から平均して約1/4重量%のコンドロイチン硫酸
(酸性ムコ多糖画分)が得られた。このようにして得た
コンドロイチン硫酸は、組成分析の結果、 C4位一硫酸化GalNAc 28.4% C6位一硫酸化GalNAc 52.8% C4、C6位一硫酸化GalNAc 7.8% 非硫酸化GalNAc 11.0% であり、硫酸基分布が従来のものよりも比較的ランダム
な構造であり、抗肥満作用に限らず生理活性でより広い
作用を期待できる。但し、本発明においては大量、安
価、安全にコンドロイチン硫酸を収得できることが重要
である。
By the above operation, about 1/4% by weight of chondroitin sulfate (acid mucopolysaccharide fraction) was obtained on average from defatted salmon / trout nasal cartilage. As a result of composition analysis, the chondroitin sulfate obtained in this manner was found to have a C4 position monosulfated GalNAc 28.4%, a C6 position monosulfated GalNAc 52.8%, and a C4, C6 position monosulfated GalNAc 7.8% non-sulfated. GalNAc is 11.0%, and the sulfate group distribution has a relatively random structure as compared with the conventional one, so that not only the anti-obesity effect but also a broader effect can be expected with physiological activity. However, in the present invention, it is important that chondroitin sulfate can be obtained in large quantities, at low cost, and safely.

【0035】シラカバ樹液は、すでに化粧品への応用が
試みられるなど、従来からその取得方法は確立されてい
る。本発明も、一般的な取得方式によって得たシラカバ
樹液を用いる。
The method of obtaining birch sap has been established, for example, the application to cosmetics has already been attempted. The present invention also uses birch sap obtained by a general acquisition method.

【0036】指摘するべきは、近時、諸外国においてシ
ラカバ樹液(カバノキ科カバノキ属の樹液も同じ)に関
する技術が報告されており、報告内容は各国において相
違するものの、少なくともわが国、韓国、中国におい
て、シラカバ樹液に利尿作用が認められる点では共通す
る傾向がみられる。同一の樹木樹液であっても。植生の
環境相違によって、或いは当該地の人的な生理活性(食
習慣の違いなど)の相違から、異なる報告が生ずる可能
性があるが、アジア太平洋沿岸地域では基本的にシラカ
バ樹液に基づく利尿効果が認められるとされる。
It should be pointed out that in recent years, techniques regarding birch sap (the same is true for birch birch sap) have been reported in other countries. Although the content of the report differs in each country, at least in Japan, Korea and China There is a common tendency in that birch sap has a diuretic effect. Even with the same tree sap. Different reports may occur due to differences in vegetation environment or differences in human bioactivity (eg, differences in dietary habits) in the area, but diuretic effects based on birch sap are basically used in the Asia Pacific coastal region. Is recognized.

【0037】本発明は、かかる点に着目し、大量かつ安
全に取得できる鮭鱒由来のコンドロイチン硫酸に加え
て、わが国および近隣諸国(韓国、太平洋沿岸の中国北
東部およびロシア地域)で取得できるシラカバ樹液を配
合することにより、特に肥満に起因する各種の関節痛症
状を解消しようとするものである。利尿促進は、風邪や
各種の軽度の疾患に効果的であることは古くから知られ
ているが、利尿による体内不純物の排出に伴う血液の浄
化作用によって、肥満防止および関節の鎮痛作用を促す
ことが出来ると考えられる。
The present invention focuses on this point and, in addition to chondroitin sulfate derived from salmon trout, which can be obtained in large quantities and safely, birch can be obtained in Japan and neighboring countries (Korea, northeastern China along the Pacific coast and Russia). By blending sap, it is intended to eliminate various joint pain symptoms particularly caused by obesity. Diuretic promotion has long been known to be effective for colds and various mild diseases, but it promotes the prevention of obesity and the analgesic action of joints by purifying blood due to the removal of body impurities by diuresis. Is thought to be possible.

【0038】シラカバ樹液のコストは、ある程度低く抑
えることが出来る。需要が少ないからである。現実的な
問題は、抗肥満作用のあるコンドロイチン硫酸の製造コ
ストにあったが、これを鮭/鱒由来のコンドロイチン硫
酸に代替することにより、シラカバ樹液を添加しても従
来の約1/3のコストで、コンドロイチン硫酸とシラカ
バ樹液の双方を含む機能性食品の製造が可能となった。
この結果、日常的、継続的に長期に渡ってコンドロイチ
ン硫酸およびシラカバ樹液の双方を含む機能性食品を摂
取できる可能性が高まり、過度な食餌制限をするまでも
なく肥満を抑制し、痛風やリューマチなどの疾患を抑制
することが可能となる。
The cost of birch sap can be kept low to some extent. This is because the demand is small. A practical problem was the production cost of chondroitin sulfate having an anti-obesity effect. By replacing this with chondroitin sulfate derived from salmon / trout, even if birch sap was added, it was about one-third of the conventional cost. The cost has enabled the production of functional foods containing both chondroitin sulfate and birch sap.
As a result, the possibility of ingesting functional foods containing both chondroitin sulfate and birch sap on a daily, continuous and long-term basis is increased, obesity is suppressed without excessive dietary restriction, and gout and rheumatism are suppressed. And other diseases can be suppressed.

【0039】シラカバ樹液は、穿孔して得た樹液を濾
過、殺菌(例えば低温加熱殺菌)して用いる。濾縮はせ
ず、樹液濃度をそのままにして用いることが望ましい。
濾縮すると熱効率が悪く、澱が生じて白濁するなど好ま
しくないからである。尚、経年取得しても樹液は枯渇し
ない。溢出量が減る場合もあるが穿孔する部位を変える
ことにより一定量の樹液を安定確保できる。
Birch sap is used by filtering and sterilizing (for example, pasteurizing at low temperature) the sap obtained by perforation. It is desirable that the sap be used as it is without being subjected to filtration.
This is because, if it is filtered, the thermal efficiency is poor, and it is not preferable that lees form and become cloudy. In addition, sap does not deplete even if acquired over time. Although the amount of extravasation may decrease, a constant amount of sap can be stably secured by changing the site to be pierced.

【0040】[0040]

【発明の効果】以上説明したように本発明に係る機能性
食品によれば、腸管におけるグルコース吸収を遅らせ血
糖値の急激な上昇を抑えるコンドロイチン硫酸の作用に
よって過度な食餌制限をすることなく肥満を抑制し、同
時に血液を浄化しつつ利尿を促進するシラカバ樹液を配
合した機能性食品を、大量、安全、安価に製品供給する
ことが可能となる。
As described above, according to the functional food of the present invention, obesity can be reduced without excessively restricting the diet by the action of chondroitin sulfate, which delays the absorption of glucose in the intestinal tract and suppresses a rapid rise in blood sugar level. It is possible to supply a large quantity, a safe, and inexpensive functional food containing birch sap that suppresses, and at the same time, promotes diuresis while purifying blood.

【0041】[0041]

【実施例】下記の表1は、こんにゃくゼリー()グレー
プ味の成分の一例である。作るには、原料1〜5を混合
し85℃以上で加熱し溶解する。次いで原料6,7を添
加しpH調整を行う(好ましくはpH3.8)。脱気
後、原料8を添加し、70℃でカップに充填する。これ
を80℃30分殺菌し、冷却する。尚、ゲル化剤として
は例えばサンカラNo. 1865B(商標;太陽薬品)を用い
る。製品に弾力を与えるためである。コンドロイチン硫
酸の配合量は0.3〜1gの範囲である。
EXAMPLES Table 1 below shows examples of components of konjac jelly () grape flavor. To make it, raw materials 1 to 5 are mixed and heated and melted at 85 ° C. or higher. Next, the raw materials 6 and 7 are added to adjust the pH (preferably pH 3.8). After degassing, the raw material 8 is added, and the cup is filled at 70 ° C. This is sterilized at 80 ° C. for 30 minutes and cooled. As a gelling agent, for example, Sankara No. 1865B (trademark; Taiyo Yakuhin) is used. This is to give the product elasticity. The amount of chondroitin sulfate is in the range of 0.3 to 1 g.

【0042】[0042]

【表1】 [Table 1]

【0043】下記の表2は、滑らかなこんにゃく食感の
ヨーグルト風味のゼリードリンクに用いる成分の一例で
ある。作るには、原料1〜6を混合し90℃で5分間加
熱し溶解する。次いで原料7を添加しpH調整を行う。
90℃にてホットパック充填して冷却して製品を得る。
尚、ゲル化剤としては例えばサンカラNo. 2030を用い
る。耐熱耐酸性に優れるからである。コンドロイチン硫
酸の配合量は0.3〜1gの範囲である。
Table 2 below is an example of the ingredients used for a yogurt flavored jelly drink having a smooth konjac texture. To make it, materials 1 to 6 are mixed and heated at 90 ° C. for 5 minutes to dissolve. Next, the raw material 7 is added and the pH is adjusted.
Hot pack at 90 ° C and cool to obtain product.
As the gelling agent, for example, Sankara No. 2030 is used. This is because it is excellent in heat resistance and acid resistance. The amount of chondroitin sulfate is in the range of 0.3 to 1 g.

【0044】[0044]

【表2】 [Table 2]

【0045】下記の表3は、滑らかなこんにゃく食感の
グレープフルーツゼリードリンクに用いる成分の一例で
ある。作るには、原料1〜5を混合し90℃で5分間加
熱し溶解する。次いで原料6を添加し、原料7でpH調
整を行う。原料8を添加し、90℃にてホットパック充
填して冷却し製品を得る。尚、ゲル化剤としては例えば
サンカラNo. 2030を用いる。耐熱耐酸性に優れるからで
ある。コンドロイチン硫酸の配合量は0.3〜1gの範
囲である。
Table 3 below shows an example of ingredients used for a grapefruit jelly drink having a smooth konjac texture. To make it, materials 1 to 5 are mixed and heated at 90 ° C. for 5 minutes to dissolve. Next, the raw material 6 is added, and the pH of the raw material 7 is adjusted. Raw material 8 is added, and hot-packed at 90 ° C. to cool and obtain a product. As the gelling agent, for example, Sankara No. 2030 is used. This is because it is excellent in heat resistance and acid resistance. The amount of chondroitin sulfate is in the range of 0.3 to 1 g.

【表3】 [Table 3]

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 35/78 A61P 3/04 A61P 3/04 19/02 19/02 19/06 19/06 A23L 2/00 F E Fターム(参考) 4B017 LC03 LE05 LG20 LK13 LP01 4B018 LB08 LE04 MD33 MD48 MD74 ME01 ME14 MF01 MF05 MF07 MF11 MF12 4C086 AA01 EA26 MA02 MA04 MA27 MA52 NA10 NA14 ZA70 ZA96 ZB15 ZC75 4C087 AA01 BB29 CA14 CA39 MA02 MA27 MA52 NA10 NA14 ZA70 ZA96 ZB15 ZC75 4C088 AB25 AC08 AD11 BA06 MA08 MA27 MA52 NA10 NA14 ZA70 ZA96 ZB15 ZC75 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI theme coat ゛ (Reference) A61K 35/78 A61P 3/04 A61P 3/04 19/02 19/02 19/06 19/06 A23L 2 / 00 FEF term (reference) 4B017 LC03 LE05 LG20 LK13 LP01 4B018 LB08 LE04 MD33 MD48 MD74 ME01 ME14 MF01 MF05 MF07 MF11 MF12 4C086 AA01 EA26 MA02 MA04 MA27 MA52 NA10 NA14 ZA70 ZA96 ZB15 ZC754CA02 MA27 ZA70 ZA96 ZB15 ZC75 4C088 AB25 AC08 AD11 BA06 MA08 MA27 MA52 NA10 NA14 ZA70 ZA96 ZB15 ZC75

Claims (5)

【特許請求の範囲】[Claims] 【請求項1】鮭または鱒の鼻軟骨由来のコンドロイチン
硫酸と、カバノキ科カバノキ属樹木の樹液とを含む機能
性食品。
1. A functional food comprising chondroitin sulfate derived from nasal cartilage of salmon or trout and sap of a birch tree of the birch family.
【請求項2】前記機能性食品は、鮭または鱒の鼻軟骨由
来のコンドロイチン硫酸を主成分とする軟質ゼリー状と
することを特徴とする請求項1記載の機能性食品。
2. The functional food according to claim 1, wherein the functional food is in the form of a soft jelly mainly composed of chondroitin sulfate derived from nasal cartilage of salmon or trout.
【請求項3】前記機能性食品は、カバノキ科カバノキ属
樹木の樹液を主成分とする液状飲料とすることを特徴と
する請求項1記載の機能性食品。
3. The functional food according to claim 1, wherein said functional food is a liquid beverage containing a sap of a birch tree of the birch family.
【請求項4】前記コンドロイチン硫酸は、鮭または鱒の
鼻軟骨を粉砕して脱脂し、アルカリを用いて分解させた
後、酵素処理を施して精製抽出することを特徴とする請
求項1〜請求項3記載の機能性食品。
4. The chondroitin sulfate is characterized in that salmon or trout nasal cartilage is pulverized and defatted, decomposed with an alkali, and then subjected to enzymatic treatment for purification and extraction. Item 4. The functional food according to item 3.
【請求項5】前記鮭または鱒の鼻軟骨の粉砕は、マイナ
ス30〜60℃の低温条件下で行うことを特徴とする請
求項4記載の機能性食品。
5. The functional food according to claim 4, wherein the nose cartilage of salmon or trout is pulverized at a low temperature of -30 to 60 ° C.
JP2000044242A 2000-02-22 2000-02-22 Functional food Expired - Fee Related JP4034024B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000044242A JP4034024B2 (en) 2000-02-22 2000-02-22 Functional food

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000044242A JP4034024B2 (en) 2000-02-22 2000-02-22 Functional food

Publications (2)

Publication Number Publication Date
JP2001231497A true JP2001231497A (en) 2001-08-28
JP4034024B2 JP4034024B2 (en) 2008-01-16

Family

ID=18567032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000044242A Expired - Fee Related JP4034024B2 (en) 2000-02-22 2000-02-22 Functional food

Country Status (1)

Country Link
JP (1) JP4034024B2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247602A (en) * 2000-03-02 2001-09-11 Mitsuo Takai Salmon-derived chondroitin sulfuric acid
WO2003097081A1 (en) * 2002-05-20 2003-11-27 Maruha Corporation Composition for treating or preventing hyperuricemia
WO2004039994A1 (en) * 2002-11-01 2004-05-13 Nippon Barrier Free Co., Ltd. Sodium chondroitin sulfate, chondroitin sulfate-containing material and processes for producing the same
KR20040049746A (en) * 2002-12-07 2004-06-12 강태훈 Crushed pieces of a maple leaf and sap of aceraceae using for diet
JP2004189825A (en) * 2002-12-10 2004-07-08 Biochem:Kk Method for producing sodium chondroitin sulfate
JP2005255727A (en) * 2004-03-09 2005-09-22 Tokuyama Corp Method for producing highly purified mucopolysaccharide
JP2005350564A (en) * 2004-06-10 2005-12-22 Tokuyama Corp Method for producing chondroitin sulfate
WO2007037297A1 (en) * 2005-09-29 2007-04-05 Maruha Corporation Composition effective for prevention and treatment of adult disease
WO2011136159A1 (en) 2010-04-28 2011-11-03 日本薬品株式会社 Composition for the treatment of aesthenopia
JP2012175969A (en) * 2011-01-31 2012-09-13 Aichi Medical Univ Enzyme for degrading chondroitin or chondroitin sulfate, reagent, degrading method, method for producing highly sulfated oligosaccharide and composition
JP2013241393A (en) * 2012-04-25 2013-12-05 Rohto Pharmaceutical Co Ltd Composition for oral administration
CN112754010A (en) * 2021-01-26 2021-05-07 呼伦贝尔市林海森林经营管理有限公司 Preparation method of birch juice concentrated solution

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247602A (en) * 2000-03-02 2001-09-11 Mitsuo Takai Salmon-derived chondroitin sulfuric acid
WO2003097081A1 (en) * 2002-05-20 2003-11-27 Maruha Corporation Composition for treating or preventing hyperuricemia
WO2004039994A1 (en) * 2002-11-01 2004-05-13 Nippon Barrier Free Co., Ltd. Sodium chondroitin sulfate, chondroitin sulfate-containing material and processes for producing the same
JP2004149736A (en) * 2002-11-01 2004-05-27 Nippon Barrier Free:Kk Chondroitin sodium sulfate, chondroitin sulfate-containing substance, and method for producing them
KR20040049746A (en) * 2002-12-07 2004-06-12 강태훈 Crushed pieces of a maple leaf and sap of aceraceae using for diet
JP2004189825A (en) * 2002-12-10 2004-07-08 Biochem:Kk Method for producing sodium chondroitin sulfate
JP2005255727A (en) * 2004-03-09 2005-09-22 Tokuyama Corp Method for producing highly purified mucopolysaccharide
JP2005350564A (en) * 2004-06-10 2005-12-22 Tokuyama Corp Method for producing chondroitin sulfate
WO2007037297A1 (en) * 2005-09-29 2007-04-05 Maruha Corporation Composition effective for prevention and treatment of adult disease
US7951782B2 (en) 2005-09-29 2011-05-31 Maruha Nichiro Seafoods, Inc Composition effective to prevent or treat adult disease
WO2011136159A1 (en) 2010-04-28 2011-11-03 日本薬品株式会社 Composition for the treatment of aesthenopia
JP2012175969A (en) * 2011-01-31 2012-09-13 Aichi Medical Univ Enzyme for degrading chondroitin or chondroitin sulfate, reagent, degrading method, method for producing highly sulfated oligosaccharide and composition
JP2013241393A (en) * 2012-04-25 2013-12-05 Rohto Pharmaceutical Co Ltd Composition for oral administration
CN112754010A (en) * 2021-01-26 2021-05-07 呼伦贝尔市林海森林经营管理有限公司 Preparation method of birch juice concentrated solution

Also Published As

Publication number Publication date
JP4034024B2 (en) 2008-01-16

Similar Documents

Publication Publication Date Title
JP5276813B2 (en) Elastin-degrading peptide, method for producing elastin and its enzyme-degrading peptide
JP4505322B2 (en) Jelly drink
CN102150836A (en) Ammonia sugar peptide soft capsule
JP2001231497A (en) Functional food
CN1698448A (en) Polypeptide almond milk and preparation method thereof
CN106721855A (en) A kind of solid beverage preparation method for safeguarding men's health
CN112438356A (en) Multi-element compound peptide solid beverage and preparation method thereof
KR101883979B1 (en) pomegranate drink comprising marine collagen and manufacturing method thereof
WO2005112665A1 (en) Composition containing processed sweet potato foliage
CN107484984B (en) Stichopus japonicus oral liquid rich in Stichopus japonicus active polysaccharide and its preparation method
CN102018158A (en) Aloe jam
JP4684440B2 (en) Lipid peroxide elevation-suppressing composition containing mannooligosaccharide
CN116584604A (en) Phyllanthus emblica fruit solid beverage rich in raw fruit dietary fibers and preparation method thereof
JP2005073503A (en) Method for improving flavor of emblica officinalis gaertn or phyllanthus embilica
CN1089219C (en) Gingko juice and its production process
KR102469337B1 (en) Method for preparing antler extract and kyung-ok-go containing antler extract
JP5794678B2 (en) Glucagon-like peptide-1 secretion promoter
KR100870063B1 (en) Collagen Vita Citrus junos Tea Composition and Process for Producing of the same
CN1919033A (en) Balsam pear jam ice cream power
CN104738700B (en) A kind of loach protect liver product and preparation method thereof
CN1765190A (en) Pawpaw milk drink and its preparation process
CN104171916B (en) A kind of containing mantis shrimp head, the healthy fine dried noodles and preparation method thereof of Squilla Oratoria Shell
CN105265710A (en) Production method of kelp tabletting candies
JP3155746B1 (en) Method for producing type II collagen
CN109077207A (en) A kind of sea-buckthorn pumpkin composite fruit juice formula and its processing technology

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040526

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040617

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040617

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040623

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040617

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20050810

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051124

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20051124

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060307

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060508

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071016

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071024

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101102

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100224

LAPS Cancellation because of no payment of annual fees